Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes

July, Mose; Santhanam, Prasanna; Giovanella, Luca; Treglia, Giorgio

doi:10.1111/cpf.12391

Cited by 11 publications

(7 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, the latest evidence has shown that 68 Ga-SSA PET provides good diagnostic accuracy in detecting MEN syndromesrelated NETs higher than that of SSR scintigraphy. The 18 F-FDOPA PET seems to have a potential role in detecting MEN-2-related NETs, whereas 18 F-FDG PET is potentially useful in identifying aggressive NETs with poorer outcomes [42]. The tumor causing ECS due to adrenocorticotropic hormone (ACTH) hypersecretion is often difficult to localize on conventional imaging methods.…”

Section: Multiple Endocrine Neoplasia (Men) Syndromes and Ectopic Cushing Syndrome (Ecs)mentioning

confidence: 99%

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Treglia

Sadeghi

Giovinazzo

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in patients with neuroendocrine neoplasms. We performed an umbrella review of published meta-analyses to provide an evidence-based summary. Methods: A comprehensive literature search of meta-analyses listed in PubMed/MEDLINE and Cochrane Library databases was carried out (last search date: 30 June 2021). Results: Thirty-four published meta-analyses were selected and summarized. About the diagnostic performance: 68Ga-SSA PET yields high diagnostic performance in patients with NETs and PGL; 18F-FDOPA PET yields good diagnostic performance in patients with intestinal NETs, PGL, NB, being the best available PET method in detecting rMTC; 68Ga-exendin-4 PET has good diagnostic accuracy in detecting insulinomas; 18F-FDG PET has good diagnostic performance in detecting aggressive neuroendocrine neoplasms. About the prognostic value: 68Ga-SSA PET has a recognized prognostic value in well-differentiated NETs, whereas 18F-FDG PET has a recognized prognostic value in aggressive neuroendocrine neoplasms. A significant clinical impact of 68Ga-SSA PET and related hybrid modalities in patients with NETs was demonstrated. There are no major toxicities or safety issues related to the use of PET radiopharmaceuticals in patients with neuroendocrine neoplasms. Conclusions: Evidence-based data support the use of PET with different radiopharmaceuticals in patients with neuroendocrine neoplasms with specific indications for each radiopharmaceutical.

show abstract

Section: Multiple Endocrine Neoplasia (Men) Syndromes and Ectopic Cushing Syndrome (Ecs)mentioning

confidence: 99%

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Treglia

Sadeghi

Giovinazzo

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…Extra-adrenal PGL can be found in the organ of Zuckerkandl, at the level of the inferior mesenteric artery. Multiple endocrine neoplasia (MEN) type 2B is due to Met918Thr RET mutation in >95% cases and includes medullary thyroid carcinoma, PHEO, and extra-endocrine features ( 16 ). Penetrance for PHEO is lower (about 40-50%) than for medullary thyroid carcinoma (90%) ( 16 ).…”

Section: Pheochromocytomasmentioning

confidence: 99%

Clinical utility of nuclear imaging in the evaluation of pediatric adrenal neoplasms

et al. 2023

View full text Add to dashboard Cite

Adrenal neoplasms rarely occur in children. They can be diagnosed in the presence of endocrine, metabolic or neurological problems, an abdominal mass, more rarely an adrenal incidentaloma, or in the context of an adrenal mass discovered in the evaluation of childhood cancer including hematologic malignancy. According to standard medical practice, pediatric malignancies are almost always evaluated by 18F-fluorodeoxyglucose positron emission tomography with computed tomography ([18F]FDG PET/CT). Nuclear imaging using specific radiotracers is also an important tool for diagnosing and staging neuroblastoma, pheochromocytoma, hormone hypersecretion, or indeterminate adrenal masses. The Hippocratic oath “primum non nocere” encourages limitation of radiation in children per the ALARA concept (as low as reasonably achievable) but should not lead to the under-use of nuclear imaging because of the potential risk of inaccurate diagnosis or underestimation of the extent of disease. As in adults, nuclear imaging in children should be performed in conjunction with hormone evaluation and morphological imaging.

show abstract

“…PET is an important imaging modality in management of patients with RDs, [110][111][112] such as multiple endocrine neoplasia syndromes (MEN1, MEN2A, MEN2B), 113 tumoral calcinosis, 114 Von-Hippel Lindau (VHL), 115 familial carcinoid syndrome, 116 metastatic pheochromocytoma, and paraganglioma, 117 hemangioendothelioma, and other hereditary cancer syndromes. 118 Appropriately employing the capabilities of AI in conjunction with PET could improve monitoring and management of RDs.…”

Section: Artificial Intelligence-based Positron Emission Tomography S...mentioning

confidence: 99%

Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities

et al. 2022

View full text Add to dashboard Cite

Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes

Cited by 11 publications

References 45 publications

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Clinical utility of nuclear imaging in the evaluation of pediatric adrenal neoplasms

Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities

Contact Info

Product

Resources

About